Reviewer's report

Title: The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study

Version: 1 Date: 10 August 2011

Reviewer: Francesca Bagnato

Reviewer's report:

The paper entitled “The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study” is interesting.

This reviewer suggests clarifying:

1) The clinical characteristics of patients who tend to present injection-site reactions. In other words, it would be interesting to know if patients who have reactions, independently to which drug, have had different disease course or are in a more advanced stage of MS. Analysis regarding clinical characteristics of patients and on their relationship with site-reactions are warranted.

2) The definition of non-responder or failure to therapy after one year.

3) How baseline characteristics and injection-site reactions interfered with lack of response to therapy. In other words, were injection-site reactions an independent variable in predicting failure to drug with respect to the baseline clinical characteristics of patients?